<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01571349</url>
  </required_header>
  <id_info>
    <org_study_id>2012-02--85-001</org_study_id>
    <nct_id>NCT01571349</nct_id>
  </id_info>
  <brief_title>Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura</brief_title>
  <official_title>Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are trying to investigate the coagulation status of idiopathic (immune)
      thrombocytopenic purpura patients by measuring the platelet count, coagulation battery, von
      Willebrand factor level, thromboelastography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with chronic coagulation disorder, laboratory model and clinical data have shown
      evidence for a rebalanced hemostasis. Previous study showed that the platelet count may not
      predict the risk of bleeding since the platelet count is not an indicator of platelet
      function. Thromboelastography may be the choice of investigation when platelet function is in
      question especially in patients with idiopathic (immune) thrombocytopenic purpura (ITP).
      Previous study have shown that maximum clot formation is the most important
      thromboelastography parameter in predicting bleeding in ITP patients that makes
      thromboelastography superior to other hemostatic tests. The investigators are trying to
      evaluate the rebalanced hemostasis in patients with ITP by comparing the value of platelet
      count, von Willebrand factor antigen level, and thromboelastography parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>maximum clot formation</measure>
    <time_frame>within 3 hour of blood sampling</time_frame>
    <description>thromboelastography parameters performed within 3 hours of blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>within 1 hours of blood sampling</time_frame>
    <description>platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation battery results</measure>
    <time_frame>within 1 hour after blood sampling</time_frame>
    <description>prothrombin time (%, second, INR) activated partial thromboplastin time (sec) fibrinogen level (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>von Willebrand factor antigen</measure>
    <time_frame>within 3 hours of blood sample</time_frame>
    <description>von Willebrand factor antigen level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clotting time</measure>
    <time_frame>within 3 hours of blood sampling</time_frame>
    <description>clotting time of Thromboelastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alpha angle</measure>
    <time_frame>within 3 hours of blood sample</time_frame>
    <description>alpha angle of thromboelastography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A10, A15, A20, A25</measure>
    <time_frame>within 3 hours of blood sampling</time_frame>
    <description>amplitude 10, 15, 20, 25 minutes (mm) of thromboelastography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LY 60</measure>
    <time_frame>within 3 hours of blood sampling</time_frame>
    <description>maximum amplitude at 60 minutes of thromboelastography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLI</measure>
    <time_frame>within 3 hours of blood sampling</time_frame>
    <description>clot lysis index of thromboelastography parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum lysis</measure>
    <time_frame>within 3 hours of blood sampling</time_frame>
    <description>Maximum lysis of thromboelastography parameter</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>chronic ITP group</arm_group_label>
    <description>ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acute ITP group</arm_group_label>
    <description>ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Those who visits the outpatients clinic of Samsung Medical Center with a diagnosis of
        idiopathic (immune) thrombocytopenic purpura between March, 2012 and February, 2013.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those who visits the outpatients clinic of Samsung Medical Center with a diagnosis of
             idiopathic (immune) thrombocytopenic purpura (ITP)between March, 2012 and February,
             2013.

          -  Those with age between 20 and 70 yrs old

        Exclusion Criteria:

          -  Those with other causes of thrombocytopenia other than ITP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaab Soo Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>December 24, 2013</last_update_submitted>
  <last_update_submitted_qc>December 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Gaab Soo Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rebalanced hemostasis</keyword>
  <keyword>idiopathic thrombocytopenic purpura</keyword>
  <keyword>coagulation status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

